Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317826 | 0.69 | GPR3 (0.42) | GPR3KDM4EALDH1A1MAPTCACNA1B | |
| SCHEMBL66254 | 0.67 | GPR3 (0.40) | GPR3KDM4EALDH1A1MEN1GAA | |
| SCHEMBL767077 | 0.67 | GPR3 (0.40) | GPR3KDM4EALDH1A1MEN1GAA | |
| SCHEMBL65944 | 0.67 | GPR3 (0.40) | GPR3KDM4EALDH1A1MAPTCACNA1B | |
| SCHEMBL66184 | 0.67 | GPR3 (0.40) | GPR3KDM4EALDH1A1MAPTCACNA1B | |
| SCHEMBL2956882 | 0.64 | GPR3 (0.37) | GPR3ALDH1A1 | |
| SCHEMBL15902389 | 0.62 | — | — | |
| SCHEMBL10470919 | 0.62 | GPR3 (0.36) | GPR3KDM4EMAPT | |
| SCHEMBL3525196 | 0.62 | EPHX2 (0.36) | GPR3ALDH1A1TSHR | |
| SCHEMBL3136356 | 0.62 | GPR3 (0.36) | GPR3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652063-B2 | For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis | ALLERGAN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1327630-B1 | NEW DERIVATIVES OF CYANO-ARYL (OR CYANOHETEROARYL)-CARBONYL-PIPERAZINYL-PYRIMIDINES, THEIR PREPARATION AND APPLICATION AS MEDICATION | ESTEVE LABOR DR (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-7300937-B2 | Derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-11-27 | — | — | US | disclosed |
| US-7169807-B2 | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists | ALLERGAN, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070010495-A1 | 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS | ALLERGAN, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| WO-2005100339-A1 | 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS | ALLERGAN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050228185-A1 | For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis | ALLERGAN, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20040048872-A1 | New derivatives of cyano-aryl (or cyanoheteroaryl) -carbonyl- piperazinyl - pyrimidines, their preparation and application as medication | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2004-03-11 | — | — | US | disclosed |
| EP-1327630-A1 | NEW DERIVATIVES OF CYANO-ARYL (OR CYANOHETEROARYL)-CARBONYL-PIPERAZINYL-PYRIMIDINES, THEIR PREPARATION AND APPLICATION AS MEDICATION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-07-16 | — | — | EP | disclosed |
| US-4055556-A | PIGMENTS | SANDOZ LTD. (CH) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048872-A1 | New derivatives of cyano-aryl (or cyanoheteroaryl) -carbonyl- piperazinyl - pyrimidines, their preparation and application as medication | CBR3, CBR1, CNR1 | GPR3 300/4885KDM4E 1472/4885ALDH1A1 304/4885 |
| US-20050228185-A1 | For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis | CRHR2, HRH4, CNR2 | GPR3 143/4885KDM4E 3533/4885ALDH1A1 3053/4885 |
| US-20070010495-A1 | 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS | PTGER4, PTGER2, PTGER1 | GPR3 134/4885KDM4E 2046/4885ALDH1A1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.